Pangen Biotech Inc. Logo

Pangen Biotech Inc.

Develops biosimilars and provides CHO-based CDMO services for the global biopharma industry.

222110 | KO

Overview

Corporate Details

ISIN(s):
KR7222110009
LEI:
Country:
South Korea
Address:
경기도 수원시 영통구 신원로 306, 2동 4층(원천동 영통이노플렉스) , 수원시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pangen Biotech Inc. is a global biotechnology company specializing in the research, development, and manufacturing of biologics. The company's core business focuses on developing and commercializing high-growth biosimilar products, including Erythropoietin (EPO) and Aflibercept. Leveraging its patented platform technology centered on Chinese Hamster Ovary (CHO) cell lines, Pangen Biotech also provides comprehensive Contract Development and Manufacturing Organization (CDMO) services to other biopharmaceutical firms. The company, part of the Huons Group, aims to supply both domestic and international markets with its biologics, reagents, and development services.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-11 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 77.4 KB
2025-08-20 00:00
Pre-Annual General Meeting Information
주주총회소집결의 (임시주주총회)
Korean 11.0 KB
2025-08-20 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2025-08-13 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.5 MB
2025-08-13 00:00
Quarterly Report
[기재정정]분기보고서 (2025.03)
Korean 1.2 MB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-07-25 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-07-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-05-20 00:00
Share Issue/Capital Change
전환가액의조정
Korean 17.3 KB
2025-05-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 92.5 KB
2025-05-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-05-12 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.8 KB
2025-05-02 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 40.9 KB
2025-04-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB

Automate Your Workflow. Get a real-time feed of all Pangen Biotech Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pangen Biotech Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pangen Biotech Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.